Skip to content

Event

New Ebola prevention drug tested in Congo

Clinical trials for the drug obeldesivir, which may prevent Ebola after exposure, have begun in the Democratic Republic of Congo. Over 250 participants are currently involved, with plans to expand to 1,000.

In brief

  • Congo is testing the obeldesivir drug for Ebola prevention.
  • Clinical trials started in Ituri province.
  • More than 250 people are participating in the trials.
  • The drug was developed by the American company Gilead.
  • The study plans to expand to nearly 1,000 participants.
Covered by 2 of 6 media groups
  • Budget 1 source
  • Public money not in the collected reports
  • Media business 6 sources
  • Big capital not in the collected reports
  • Readers and grants not in the collected reports
  • Undisclosed not in the collected reports

No newsrooms from these groups in the collected reports: public money, big capital, readers and grants, undisclosed.

What are media groups?

Share of reports by media group
GroupShareCount
Media business
  • Newsroom 6
86%6 items
Budget
  • Newsroom 1
14%1 item

How we count media groups — Methodology

Report an error

    • first item
    • earliest

    У Конго випробовують препарат, який може запобігати зараженню Еболою

    • first item
    • in the wave, 35 min later
    • national desk

    У Конго тестують новий препарат проти Еболи

  • БуквиMedia business
    • first item
    • in the wave, 59 min later
    • national desk

    У Конго тестують препарат для профілактики Еболи після ...

    • first item
    • caught up, 2 h later
    • national desk

    У Конго тестують препарат, який може запобігати зараженню Еболою

    • first item
    • caught up, 3 h later
    • national desk

    У ДР Конго тестують препарат, що може запобігати Еболі після контакту з хворим

  • LB.uaMedia business
    • first item
    • caught up, 3 h later
    • national desk

    Associated Press: У ДР Конго випробовують препарат який може запобігати зараженню Еболою

  • АпострофMedia business
    • first item
    • caught up, 4 h later
    • national desk

    У ДР Конго тестують препарат, що може запобігати Еболі після контакту з хворим

Comments

Loading comments…

Allow visit statistics? PostHog keeps them (EU servers) under a random browser id — no name, no account; kept for 12 months. Vercel Speed Insights measures page speed, with no id. The site works the same without. Details